C G Parsons

Summary

Affiliation: Merz Pharmaceuticals
Country: Germany

Publications

  1. ncbi NMDA receptors as targets for drug action in neuropathic pain
    C G Parsons
    Department of Preclinical Research and Development, Merz and Co GmbH, Eckenheimer Landstrasse 100 104, D 60318 Frankfurt, Germany
    Eur J Pharmacol 429:71-8. 2001
  2. ncbi Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones
    C G Parsons
    Department of Pharmacology, Merz and Co, Frankfurt, Germany
    Neuropharmacology 37:719-27. 1998
  3. ncbi Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization
    C G Parsons
    Department of Pharmacology, Merz Co, Frankfurt am Main, Germany
    Neuropharmacology 38:85-108. 1999
  4. ncbi Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data
    C G Parsons
    Department of Pharmacological Research, Merz and Co, Frankfurt am Main, Germany
    Neuropharmacology 38:735-67. 1999
  5. ncbi A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization
    K Gilling
    Preclinical Research and Development, Merz Pharmaceuticals GmbH, Frankfurt, Germany
    J Neural Transm 114:1529-37. 2007
  6. ncbi Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists
    W Danysz
    Merz Co, Eckenheimer Landstrasse 100 104, Frankfurt, 60318, Germany
    Curr Pharm Des 8:835-43. 2002
  7. ncbi Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP
    W Zajaczkowski
    Department of Pharmacology, Merz and Co, Frankfurt M, Germany
    Neuropharmacology 36:961-71. 1997
  8. ncbi Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine
    K E Gilling
    In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer, Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:415-20. 2007
  9. ncbi The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurones
    M W Jones
    Department of Physiology, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK
    Neuropharmacology 41:50-61. 2001
  10. ncbi The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, 80804, Munich, Germany
    J Neural Transm 115:1119-26. 2008

Collaborators

  • W Danysz
  • G Rammes
  • K Gilling
  • C Jatzke
  • K E Gilling
  • M W Jones
  • C Wollenburg
  • M Vanejevs
  • A Jirgensons
  • V Kauss
  • W Zajaczkowski
  • P M Headley
  • M McClean
  • T Frankiewicz

Detail Information

Publications10

  1. ncbi NMDA receptors as targets for drug action in neuropathic pain
    C G Parsons
    Department of Preclinical Research and Development, Merz and Co GmbH, Eckenheimer Landstrasse 100 104, D 60318 Frankfurt, Germany
    Eur J Pharmacol 429:71-8. 2001
    ..Such agents might be predicted to be devoid of CNS side effects at doses producing powerful antinociception at peripheral NMDA receptors...
  2. ncbi Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones
    C G Parsons
    Department of Pharmacology, Merz and Co, Frankfurt, Germany
    Neuropharmacology 37:719-27. 1998
    ..The relevance of NMDA receptor antagonism to the anti-Parkinsonian effects of budipine remains to be established...
  3. ncbi Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization
    C G Parsons
    Department of Pharmacology, Merz Co, Frankfurt am Main, Germany
    Neuropharmacology 38:85-108. 1999
    ....
  4. ncbi Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data
    C G Parsons
    Department of Pharmacological Research, Merz and Co, Frankfurt am Main, Germany
    Neuropharmacology 38:735-67. 1999
    ....
  5. ncbi A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization
    K Gilling
    Preclinical Research and Development, Merz Pharmaceuticals GmbH, Frankfurt, Germany
    J Neural Transm 114:1529-37. 2007
    ..In view of their relatively low affinity and associated rapid kinetics, they should prove to be useful therapeutics in a wide range of CNS disorders...
  6. ncbi Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists
    W Danysz
    Merz Co, Eckenheimer Landstrasse 100 104, Frankfurt, 60318, Germany
    Curr Pharm Des 8:835-43. 2002
    ..and pain (chronic pain, inhibition of tolerance to the analgesic effects of morphine). It turn, this agent has recently entered phase II of clinical trials in alcoholism after a favourable profile seen in phase I studies...
  7. ncbi Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP
    W Zajaczkowski
    Department of Pharmacology, Merz and Co, Frankfurt M, Germany
    Neuropharmacology 36:961-71. 1997
    ..Thus, under conditions of tonic activation of NMDA receptors, uncompetitive NMDA receptor antagonists can paradoxically reverse deficits in learning and synaptic plasticity...
  8. ncbi Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine
    K E Gilling
    In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer, Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:415-20. 2007
    ..These fast agonist concentration-dependent kinetic properties, in addition to the clear voltage-dependence of memantine, are proposed to be important for the therapeutic tolerability of this compound in the treatment of AD...
  9. ncbi The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurones
    M W Jones
    Department of Physiology, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK
    Neuropharmacology 41:50-61. 2001
    ....
  10. ncbi The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, 80804, Munich, Germany
    J Neural Transm 115:1119-26. 2008
    ..It is therefore likely that NMDA receptor antagonists would be able to exert additional therapeutic effects in combination therapy with GRIs...